Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Total	Common shares	Treasury Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income / (Loss)	Accumulated Deficit
Balance, beginning of period (in shares) at Jun. 30, 2022		18,247,000
Balance, beginning of period at Jun. 30, 2022	$ 113,459	$ 2	$ (3,406)	$ 197,785	$ (4,562)	$ (76,360)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	27,072					27,072
Foreign currency translation adjustments	(2,162)				(2,162)
Changes in fair value of cash flow hedges	$ 769				769
Purchase of treasury shares (in shares)	(17,558)	(18,000)
Purchase of treasury shares	$ (276)		(276)
Provision for common stock warrants	856			856
Issue of common shares (in shares)		103,000
Issuance of common shares	1,827			1,827
Forfeiture of restricted common shares		(68,000)
Share-based compensation expense	2,823			2,823
Balance, end of period (in shares) at Mar. 31, 2023		18,264,000
Balance, end of period at Mar. 31, 2023	144,368	$ 2	(3,682)	203,291	(5,955)	(49,288)
Balance, beginning of period (in shares) at Dec. 31, 2022		18,298,000
Balance, beginning of period at Dec. 31, 2022	131,723	$ 2	(3,682)	201,102	(5,132)	(60,567)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	11,279					11,279
Foreign currency translation adjustments	(1,039)				(1,039)
Changes in fair value of cash flow hedges	216				216
Provision for common stock warrants	260			260
Issue of common shares (in shares)		34,000
Issuance of common shares	618			618
Forfeiture of restricted common shares		(68,000)
Share-based compensation expense	1,311			1,311
Balance, end of period (in shares) at Mar. 31, 2023		18,264,000
Balance, end of period at Mar. 31, 2023	$ 144,368	$ 2	(3,682)	203,291	(5,955)	(49,288)
Balance, beginning of period (in shares) at Jun. 30, 2023	18,280,419	18,280,000
Balance, beginning of period at Jun. 30, 2023	$ 149,964	$ 2	(3,682)	204,734	(6,312)	(44,778)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	23,810					23,810
Foreign currency translation adjustments	(310)				(310)
Changes in fair value of cash flow hedges	$ 70				70
Purchase of treasury shares (in shares)	(1,124,876)	(1,125,000)
Purchase of treasury shares	$ (18,551)		(18,551)
Provision for common stock warrants	893			893
Issue of common shares (in shares)		59,000
Issuance of common shares	362			362
Share-based compensation expense	$ 3,073			3,073
Balance, end of period (in shares) at Mar. 31, 2024	17,214,446	17,214,000
Balance, end of period at Mar. 31, 2024	$ 159,311	$ 2	(22,233)	209,062	(6,552)	(20,968)
Balance, beginning of period (in shares) at Dec. 31, 2023		17,681,000
Balance, beginning of period at Dec. 31, 2023	156,113	$ 2	(14,116)	207,638	(6,133)	(31,278)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	10,310					10,310
Foreign currency translation adjustments	(288)				(288)
Changes in fair value of cash flow hedges	$ (131)				(131)
Purchase of treasury shares (in shares)	(501,549)	(502,000)
Purchase of treasury shares	$ (8,117)		(8,117)
Provision for common stock warrants	299			299
Issue of common shares (in shares)		35,000
Issuance of common shares	351			351
Share-based compensation expense	$ 774			774
Balance, end of period (in shares) at Mar. 31, 2024	17,214,446	17,214,000
Balance, end of period at Mar. 31, 2024	$ 159,311	$ 2	$ (22,233)	$ 209,062	$ (6,552)	$ (20,968)